Standout Papers
- Lecanemab in Early Alzheimer’s Disease (2022)
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody (2021)
- Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study (2022)
- The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease (2022)
- Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease (2024)
Immediate Impact
1 by Nobel laureates 2 from Science/Nature 72 standout
Citing Papers
Glycocalyx dysregulation impairs blood–brain barrier in ageing and disease
2025 StandoutNatureNobel
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
2025 Standout
Works of Lynn D. Kramer being referenced
Lecanemab in Early Alzheimer’s Disease
2022 Standout
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
2021 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Lynn D. Kramer | 2248 | 1919 | 720 | 874 | 60 | 4.5k | |
| Andrew Satlin | 1842 | 2076 | 888 | 944 | 104 | 6.7k | |
| Shobha Dhadda | 2392 | 1493 | 376 | 838 | 66 | 4.9k | |
| Michelle Gee | 1596 | 1237 | 497 | 718 | 24 | 3.4k | |
| Anton P. Porsteinsson | 2317 | 2845 | 371 | 716 | 126 | 5.7k | |
| Lon S. Schneider | 2708 | 3207 | 610 | 1035 | 84 | 7.7k | |
| Karen L. Bell | 2607 | 3607 | 656 | 558 | 68 | 6.8k | |
| H. Michael Arrighi | 2038 | 1863 | 303 | 1005 | 51 | 6.1k | |
| Kimberly Schafer | 1843 | 1488 | 352 | 623 | 38 | 4.6k | |
| Michael S. Rafii | 1590 | 1161 | 385 | 918 | 106 | 4.3k | |
| María M. Corrada | 3010 | 2592 | 564 | 837 | 165 | 7.2k |
All Works
Loading papers...